Pipeline Database
UB669
Search clinical-stage assets by therapeutic area, modality, target, indication, stage and territory — then inquire on any row that fits your brief.
UB669
IndicationsAlzheimer's disease
ClinicalCN - Preclinical
TherapeuticsNeurology
ModalitiesNucleic Acid Therapeutics
Exclusive Summary
- First-in-class CPP (cell-penetrating peptide) siRNA for Alzheimer’s disease, targeting a potential market of $2 billion.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →